title: Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.
abstract: Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the level of cost analyses on first-line chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Given the scarcity of cost analyses of first-line chemotherapy for NHL, it is difficult to assess the economic impact of upcoming new treatment modalities. Therefore we performed an analysis on costs of diagnosis and treatment of patients with newly diagnosed NHL who were treated with standard CHOP (-like) chemotherapy. As many NHL patients are treated in trials and the economic effects of the trial participation are unknown, our analysis included both patients treated according to trial protocols and patients treated according to standard local practice (SLP). The cost analysis was based on the total medical consumption of the patients. It was found that costs of the trial and SLP groups are within comparable ranges, although costs of diagnostic tests were somewhat higher within the trials. In elderly patients, SLP chemotherapy was discontinued more frequently in case of leucocytopenia or thrombocytopenia. This analysis provides basic information about the costs of first-line standard chemotherapy for patients with newly diagnosed aggressive NHL and the plausible ranges in which these costs may vary. Given the results, we will initiate larger studies to investigate whether trial treatments (showing more or less similar costs as SLP treatments) are more cost-effective for patients with aggressive NHL.
authors.affiliation: Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, The Netherlands. vanagthoven@bmg.eur.nl
authors.forename: M
authors.initials: M
authors.lastname: van Agthoven
authors.forename: L M
authors.initials: LM
authors.lastname: Faber
authors.forename: C A
authors.initials: CA
authors.lastname: Uyl-de Groot
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.forename: L F
authors.initials: LF
authors.lastname: Verdonck
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: J C
authors.initials: JC
authors.lastname: Kluin-Nelemans
authors.forename: B
authors.initials: B
authors.lastname: Löwenberg
authors.forename: P C
authors.initials: PC
authors.lastname: Huijgens
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D003520:Cyclophosphamide / Q000191:economics* / Q000627:therapeutic use; D004317:Doxorubicin / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000191:economics*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000191:economics* / Q000627:therapeutic use; D014750:Vincristine / Q000191:economics* / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone